VEGFA and neoplasm: Bevacizumab is a monoclonal antibody that inhibits blood vessel growth and can highly bind to vascular endothelial growth factor, thereby reducing the blood supply to the tumor, blocking the supply chain of nutrients and substances needed for tumor growth, and then inhibiting tumor progression.